Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

Abstract Background Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes. NK cells and T-lymphocytes mediate early killing of targets through a common granzyme B-dependent mechanism. Tumor c...

Full description

Bibliographic Details
Main Authors: Jay Friedman, Megan Morisada, Lillian Sun, Ellen C. Moore, Michelle Padget, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro, Clint T. Allen
Format: Article
Language:English
Published: BMJ Publishing Group 2018-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40425-018-0374-2
id doaj-9452867cafaa4abaadb8103de56db9b3
record_format Article
spelling doaj-9452867cafaa4abaadb8103de56db9b32020-11-25T02:19:41ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262018-06-016111210.1186/s40425-018-0374-2Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapiesJay Friedman0Megan Morisada1Lillian Sun2Ellen C. Moore3Michelle Padget4James W. Hodge5Jeffrey Schlom6Sofia R. Gameiro7Clint T. Allen8Translational Tumor Immunology Program, National Institutes on Deafness and Other Communication Disorders, National Institutes of HealthTranslational Tumor Immunology Program, National Institutes on Deafness and Other Communication Disorders, National Institutes of HealthTranslational Tumor Immunology Program, National Institutes on Deafness and Other Communication Disorders, National Institutes of HealthTranslational Tumor Immunology Program, National Institutes on Deafness and Other Communication Disorders, National Institutes of HealthLaboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of HealthLaboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of HealthLaboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of HealthLaboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of HealthTranslational Tumor Immunology Program, National Institutes on Deafness and Other Communication Disorders, National Institutes of HealthAbstract Background Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes. NK cells and T-lymphocytes mediate early killing of targets through a common granzyme B-dependent mechanism. Tumor cell resistance to granzyme B and how this alters NK cell killing is not clearly defined. Methods Tumor cell sensitivity to cultured murine KIL and human high affinity NK (haNK) cells in the presence or absence of AZD1775, a small molecule inhibitor of WEE1 kinase, was assessed via real time impedance analysis. Mechanisms of enhanced sensitivity to NK lysis were determined and in vivo validation via adoptive transfer of KIL cells into syngeneic mice was performed. Results Cultured murine KIL cells lyse murine oral cancer 2 (MOC2) cell targets more efficiently than freshly isolated peripheral murine NK cells. MOC2 sensitivity to granzyme B-dependent KIL cell lysis was enhanced by inhibition of WEE1 kinase, reversing G2/M cell cycle checkpoint activation and resulting in enhanced DNA damage and apoptosis. Treatment of MOC2 tumor-bearing wild-type C57BL/6 mice with AZD1775 and adoptively transferred KIL cells resulted in enhanced tumor growth control and survival over controls or either treatment alone. Validating these findings in human models, WEE1 kinase inhibition sensitized two human head and neck cancer cell lines to direct lysis by haNK cells. Further, WEE1 kinase inhibition sensitized these cell lines to antibody-dependent cell-mediated cytotoxicity when combined with the anti-PD-L1 IgG1 mAb Avelumab. Conclusions Tumor cell resistance to granzyme B-induced cell death can be reversed through inhibition of WEE1 kinase as AZD1775 sensitized both murine and human head and neck cancer cells to NK lysis. These data provide the pre-clinical rationale for the combination of small molecules that reverse cell cycle checkpoint activation and NK cellular therapies.http://link.springer.com/article/10.1186/s40425-018-0374-2NK cellsResistanceDNA damage checkpointWEE1 kinasehaNK cellsKIL cells
collection DOAJ
language English
format Article
sources DOAJ
author Jay Friedman
Megan Morisada
Lillian Sun
Ellen C. Moore
Michelle Padget
James W. Hodge
Jeffrey Schlom
Sofia R. Gameiro
Clint T. Allen
spellingShingle Jay Friedman
Megan Morisada
Lillian Sun
Ellen C. Moore
Michelle Padget
James W. Hodge
Jeffrey Schlom
Sofia R. Gameiro
Clint T. Allen
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
Journal for ImmunoTherapy of Cancer
NK cells
Resistance
DNA damage checkpoint
WEE1 kinase
haNK cells
KIL cells
author_facet Jay Friedman
Megan Morisada
Lillian Sun
Ellen C. Moore
Michelle Padget
James W. Hodge
Jeffrey Schlom
Sofia R. Gameiro
Clint T. Allen
author_sort Jay Friedman
title Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
title_short Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
title_full Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
title_fullStr Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
title_full_unstemmed Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
title_sort inhibition of wee1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2018-06-01
description Abstract Background Natural killer (NK) cells recognize and lyse target tumor cells in an MHC-unrestricted fashion and complement antigen- and MHC-restricted killing by T-lymphocytes. NK cells and T-lymphocytes mediate early killing of targets through a common granzyme B-dependent mechanism. Tumor cell resistance to granzyme B and how this alters NK cell killing is not clearly defined. Methods Tumor cell sensitivity to cultured murine KIL and human high affinity NK (haNK) cells in the presence or absence of AZD1775, a small molecule inhibitor of WEE1 kinase, was assessed via real time impedance analysis. Mechanisms of enhanced sensitivity to NK lysis were determined and in vivo validation via adoptive transfer of KIL cells into syngeneic mice was performed. Results Cultured murine KIL cells lyse murine oral cancer 2 (MOC2) cell targets more efficiently than freshly isolated peripheral murine NK cells. MOC2 sensitivity to granzyme B-dependent KIL cell lysis was enhanced by inhibition of WEE1 kinase, reversing G2/M cell cycle checkpoint activation and resulting in enhanced DNA damage and apoptosis. Treatment of MOC2 tumor-bearing wild-type C57BL/6 mice with AZD1775 and adoptively transferred KIL cells resulted in enhanced tumor growth control and survival over controls or either treatment alone. Validating these findings in human models, WEE1 kinase inhibition sensitized two human head and neck cancer cell lines to direct lysis by haNK cells. Further, WEE1 kinase inhibition sensitized these cell lines to antibody-dependent cell-mediated cytotoxicity when combined with the anti-PD-L1 IgG1 mAb Avelumab. Conclusions Tumor cell resistance to granzyme B-induced cell death can be reversed through inhibition of WEE1 kinase as AZD1775 sensitized both murine and human head and neck cancer cells to NK lysis. These data provide the pre-clinical rationale for the combination of small molecules that reverse cell cycle checkpoint activation and NK cellular therapies.
topic NK cells
Resistance
DNA damage checkpoint
WEE1 kinase
haNK cells
KIL cells
url http://link.springer.com/article/10.1186/s40425-018-0374-2
work_keys_str_mv AT jayfriedman inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT meganmorisada inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT lilliansun inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT ellencmoore inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT michellepadget inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT jameswhodge inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT jeffreyschlom inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT sofiargameiro inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
AT clinttallen inhibitionofwee1kinaseandcellcyclecheckpointactivationsensitizesheadandneckcancerstonaturalkillercelltherapies
_version_ 1724875043707551744